Author： Millington-Ward S.
Publisher： Oxford University Press
ISSN： 1460-2083
Source： Human Molecular Genetics, Vol.11, Iss.19, 2002-07, pp. : 2201-2206
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Over 100 dominant-negative mutations within the COL1A1 gene have been identified in osteogenesis imperfecta (OI). In terms of human therapeutics, targeting each of these mutations independently is unlikely to be feasible. Here we show that the hammerhead ribozyme Rzpol1a1, targeting a common polymorphism within transcripts from the COL1A1 gene, downregulates COL1A1 transcript in human mesenchymal progenitor cells at a ribozyme to transcript ratio of only 1:1. Downregulation was confirmed at the protein level. Transducing stem cells with Rzpol1A1 ex vivo followed by autologous transplantation could provide a gene therapy for a large proportion of OI patients with gain-of-function mutations using a single therapeutic.
Related content
By Bodian Dale L. Chan Ting-Fung Poon Annie Schwarze Ulrike Yang Kathleen Byers Peter H. Kwok Pui-Yan Klein Teri E.
Human Molecular Genetics, Vol. 18, Iss. 10, 2009-05 ,pp. :
Access to resources
Recommend
By Bodian Dale L. Chan Ting-Fung Poon Annie Schwarze Ulrike Yang Kathleen Byers Peter H. Kwok Pui-Yan Klein Teri E.
Human Molecular Genetics, Vol. 18, Iss. 3, 2009-02 ,pp. :
By Thiele Frank Cohrs Christian M. Flor Armando Lisse Thomas S. Przemeck Gerhard K. H. Horsch Marion Schrewe Anja Gailus-Durner Valerie Ivandic Boris Katus Hugo A. Wurst Wolfgang Reisenberg Catherine Chaney Hollis Fuchs Helmut Hans Wolfgang Beckers Johannes Marini Joan C. Hrabé de Angelis Martin
Human Molecular Genetics, Vol. 21, Iss. 16, 2012-08 ,pp. :
Osteogenesis Imperfecta: A Review with Clinical Examples
Molecular Syndromology, Vol. 2, Iss. 1, 2011-10 ,pp. :